Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement
07 mars 2022 08h00 HE
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene...
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors
20 janv. 2022 07h30 HE
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
13 janv. 2022 08h30 HE
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and...
Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
17 déc. 2021 08h00 HE
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index
14 déc. 2021 08h47 HE
|
Brooklyn ImmunoTherapeutics, Inc.
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
02 déc. 2021 08h00 HE
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality
29 nov. 2021 08h00 HE
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition
19 nov. 2021 06h00 HE
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange...
Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results
09 nov. 2021 16h35 HE
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and...
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq
14 oct. 2021 16h15 HE
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...